Hepatocellular Carcinoma (HCC): Recent Updates and Evolving Treatment Paradigms

home / peer-exchange / hepatocellular-carcinoma-hcc-recent-updates-and-evolving-treatment-paradigms

Experts review recent updates in the treatment of HCC and discuss how evidence from clinical trials and real-world settings can be applied to clinical practice to improve patient outcomes.

EP. 1: Overview of Hepatocellular Carcinoma (HCC)

By Rachna T. Shroff, MD, University of Arizona Cancer Center
Manish Shah, MD

July 12th 2023

Experts provide an overview of hepatocellular carcinoma, including the risk factors and prognosis.

EP. 2: Diagnosing Patients With Hepatocellular Carcinoma

By Rachna T. Shroff, MD, University of Arizona Cancer Center
Manish Shah, MD

July 12th 2023

Key opinion leaders review the process of diagnosing HCC, the role of molecular testing, and associated challenges.

EP. 3: Factoring Stage and Hepatic Function Into Treatment Decision-Making for HCC

By Rachna T. Shroff, MD, University of Arizona Cancer Center
Manish Shah, MD

July 19th 2023

The panel explains the Child-Pugh scoring system and how staging and liver function impact treatment decisions for patients with HCC.

EP. 4: Treatment Approaches for Patients With Early-Stage HCC

By Rachna T. Shroff, MD, University of Arizona Cancer Center
Manish Shah, MD

July 19th 2023

Manish Shah, MD, details the role of locoregional therapy in HCC, and Julio Gutierrez, MD, comments on transplant as a curative option.

EP. 5: The Role of Adjuvant Therapy in Patients With Early-Stage HCC

By Rachna T. Shroff, MD, University of Arizona Cancer Center
Manish Shah, MD

July 28th 2023

Experts review data from IMbrave050 on the potential role of atezolizumab plus bevacizumab in the adjuvant setting for HCC.

EP. 6: Updates in First-Line Systemic Therapy for Advanced HCC: The IMbrave150 Trial

By Rachna T. Shroff, MD, University of Arizona Cancer Center
Manish Shah, MD

July 28th 2023

Julio Gutierrez, MD, and Ghassan K. Abou-Alfa, MD, discuss the results of the IMbrave150 study investigating atezolizumab plus bevacizumab in the first-line setting for advanced HCC.

EP. 7: Updates in First-Line Systemic Therapy for Advanced HCC: The HIMALAYA Study

By Rachna T. Shroff, MD, University of Arizona Cancer Center
Manish Shah, MD

August 3rd 2023

Dr Manish Shah reviews data from the HIMALAYA study on front-line systemic therapy in advanced HCC with tremelimumab plus durvalumab.

EP. 8: Optimal Sequencing in Patients With Advanced HCC

By Rachna T. Shroff, MD, University of Arizona Cancer Center
Manish Shah, MD

August 3rd 2023

Key opinion leaders discuss the sequencing of systemic therapy options for patients with advanced HCC.

EP. 9: Safety Profiles of Available Therapies in Advanced HCC

By Rachna T. Shroff, MD, University of Arizona Cancer Center
Manish Shah, MD

August 9th 2023

Dr Ghassan K. Abou-Alfa explains the safety profiles of the discussed frontline therapy options for advanced HCC.

EP. 10: The Future of HCC Treatment

By Rachna T. Shroff, MD, University of Arizona Cancer Center
Manish Shah, MD

August 9th 2023

The panel closes their discussion by highlighting exciting developments on the horizon for the treatment of HCC.

EP. 11: First-Line Systemic Treatment Options for Patients With Advanced HCC

By R. Katie Kelley, MD

August 11th 2023

R. Katie Kelley, MD, provides an overview of the first-line systemic treatment options for patients with advanced hepatocellular carcinoma.

EP. 12: Tremelimumab Plus Durvalumab in Patients With Advanced HCC: The HIMALAYA Study

By R. Katie Kelley, MD

August 11th 2023

Dr R. Katie Kelley shares her thoughts on the four-year updated survival and efficacy data from the phase 3 HIMALAYA trial in patients with advanced hepatocellular carcinoma.

EP. 13: Key Safety Outcomes From Updated Analysis of HIMALAYA Trial in Advanced HCC

By R. Katie Kelley, MD

August 18th 2023

R. Katie Kelley, MD, discusses updated safety data on tremelimumab plus durvalumab for patients with advanced hepatocellular carcinoma.

EP. 14: The CELESTIAL Study: Cabozantinib Monotherapy in Advanced HCC Treatment

By R. Katie Kelley, MD

August 18th 2023

Dr R. Katie Kelley explains the design and results of the phase 3 CELESTIAL study investigating single-agent cabozantinib for the treatment of advanced hepatocellular carcinoma.

EP. 15: Safety and Efficacy Data From the Retrospective Analysis of the CELESTIAL Study in Advanced HCC

By R. Katie Kelley, MD

August 22nd 2023

R. Katie Kelley, MD, comments on the safety and efficacy data from the retrospective analysis of the CELESTIAL study in advanced hepatocellular carcinoma.

EP. 16: Future of Advanced HCC Treatment

By R. Katie Kelley, MD

August 22nd 2023

Dr R. Katie Kelley highlights other abstracts presented at World GI 2023 and shares what she looks forward to in the future of advanced hepatocellular carcinoma treatment.